P A Reece|M Peikert - JoVE Visualize

Showing results (11-20 of 35) with videos related to

Pageof 4

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986

Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatinP A Reece, I Stafford, J Russell, et al.

British Journal of Clinical Pharmacology|August 1, 1985

Prednisolone protein binding in renal transplant patientsP A Reece, A P Disney, I Stafford, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1989

Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancerP A Reece, I Stafford, M Davy, et al.

The Journal of Dermatologic Surgery and Oncology|November 1, 1994

The efficacy of various degreasing agents used in trichloroacetic acid peelsJ M Peikert, N A Krywonis, E B Rest, et al.

Clinical Pharmacology and Therapeutics|April 1, 1996

Inhibition of tacrine oral clearance by cimetidineS T Forgue, P A Reece, A J Sedman, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1987

A model for ultrafilterable plasma platinum disposition in patients treated with cisplatinP A Reece, I Stafford, J Russell, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987

Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicityP A Reece, I Stafford, J Russell, et al.

Therapeutic Drug Monitoring|January 1, 1986

Direct measurement of salicylphenolic glucuronide in human urineD M Imhoff, P A Reece, E Dimitriadis, et al.

Journal of Pharmaceutical Sciences|February 1, 1985

Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteersP A Reece, I Stafford, R H Prager, et al.

Cancer Research|June 1, 1987

Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancerP A Reece, R G Morris, J F Bishop, et al.

Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:

Pageof 4

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986

Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatinP A Reece, I Stafford, J Russell, et al.

British Journal of Clinical Pharmacology|August 1, 1985

Prednisolone protein binding in renal transplant patientsP A Reece, A P Disney, I Stafford, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1989

Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancerP A Reece, I Stafford, M Davy, et al.

The Journal of Dermatologic Surgery and Oncology|November 1, 1994

The efficacy of various degreasing agents used in trichloroacetic acid peelsJ M Peikert, N A Krywonis, E B Rest, et al.

Clinical Pharmacology and Therapeutics|April 1, 1996

Inhibition of tacrine oral clearance by cimetidineS T Forgue, P A Reece, A J Sedman, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1987

A model for ultrafilterable plasma platinum disposition in patients treated with cisplatinP A Reece, I Stafford, J Russell, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987

Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicityP A Reece, I Stafford, J Russell, et al.

Therapeutic Drug Monitoring|January 1, 1986

Direct measurement of salicylphenolic glucuronide in human urineD M Imhoff, P A Reece, E Dimitriadis, et al.

Journal of Pharmaceutical Sciences|February 1, 1985

Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteersP A Reece, I Stafford, R H Prager, et al.

Cancer Research|June 1, 1987

Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancerP A Reece, R G Morris, J F Bishop, et al.

Pageof 4